EU Drug and Medtech Regulation: a Deliberate Shift in Power Away from Member States

In the field of pharmaceutical and medical device regulation in the EU, power is increasingly moving from member states to Brussels. This is largely a good thing for the life sciences industry as it will make Europe more competitive internationally.

This article was published in the August 2013 issue of Scrip Regulatory Affairs.